ClinicalTrials.gg
Active, not recruitingNCT07457541Updated Jun 25, 2026

Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI

A Phase 1 interventional study of [99mTc]Tc-HYNIC-FAPI in Lung Cancer (Locally Advanced or Metastatic), Pancreas Cancer, Metastatic and Breast Cancer (Locally Advanced or Metastatic), sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences. Active, not recruiting at 1 site in Russia. Open to participants aged 18 Years to 75 Years. Per ClinicalTrials.gov, last updated 2026-06-25.

Sponsored by Tomsk National Research Medical Center of the Russian Academy of Sciences · Phase 1, Interventional, and Diagnostic

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
18 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 20 studies in Lung Neoplasms with a site in Russia — 3 open to participants now, 11 under way, 4 of them phase 3. Lung Neoplasms · Russia.

Planned enrollment
18th of 19
15 · median 118
Started
2026
the only one that year
Phase 1
4 of 20
none open now
Primary completion
2026-12
later than 5 of 10 live
Registered
20th of 20
by date
Lead sponsor
2 of 20
Tomsk National Research Medical Center of the Russian Academy of Sciences

Among the 20 studies in Lung Neoplasms with a site in Russia, this one is the 18th largest by planned enrollment of the 19 interventional ones that give a count, is the only one that started in 2026, is one of 4 in phase 1, reaches primary completion later than 5 of the 10 other live ones, and was the 20th registered.

Lung Neoplasms

5,436 studies on the registry are indexed under Lung Neoplasms; 1,350 are open to participants now.

Browse Lung Neoplasms studies →

Open to participants now

3 of the 20 studies in Lung Neoplasms with a site in Russia are open now. Recruiting first, the newest first:

All 3 open studies →

A study can be open while its sites in Russia have not opened yet or have stopped. Only those recruiting at a site in Russia →

Who these studies take

Of the 997 Lung Neoplasms studies recruiting now, 686 (69%) set no upper age limit and 143 (14%) stop at 75 or younger; 45 take children under 18; 143 take healthy volunteers.

This study: 18 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies in Lung Neoplasms with a site in Russia, or all of them as a file.
02

Study summary

The study should evaluate the biological distribution of 99mTc-HYNIC-FAPI in metastatic cancer patients.

Read the detailed description

The primary objective are:

  1. To assess the distribution of [99mTc]Tc- HYNIC-FAPI in normal tissues and tumors at different time intervals.
  2. To evaluate dosimetry of [99mTc]Tc- HYNIC-FAPI.
  3. To study the safety and tolerability of the drug [99mTc]Tc- HYNIC-FAPI after a single injection in a diagnostic dosage.

The secondary objective are:

1. To compare the obtained [99mTc]Tc- HYNIC-FAPI SPECT imaging results with the data of CT and/or MRI and/or ultrasound examination and immunohistochemical (IHC) studies in metastatic cancer patients.

03

Conditions studied

  • Lung Cancer (Locally Advanced or Metastatic)
  • Pancreas Cancer, Metastatic
  • Breast Cancer (Locally Advanced or Metastatic)
  • Colorectal Cancer (Locally Advanced or Metastatic)

Keywords

  • Metastatic cancer
  • Fibroblast Activation Protein
  • [99mTc]Tc-HYNIC-FAPI
  • SPECT/CT
04

Who can participate

Ages eligible
18 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subject is > 18 years of age
  • Clinical and radiological diagnosis of cancer with histological verification.
  • White blood cell count: > 2.0 x 10\^9/L
  • : > 80 g/L
  • : > 50.0 x 10\^9/L
  • =\< 2.0 times
  • Serum creatinine: Within Normal Limits
  • Blood glucose level not more than 5.9 mmol/L
  • A negative pregnancy test (serum beta-human chorionic gonadotropin, beta-HCG) at screening for all patients of . Sexually active women of childbearing potential participating in the study must use a medically acceptable form of for at least 30 days after study termination
  • Subject is capable to undergo the diagnostic investigations to be performed in the study

Exclusion criteria

Exclusion Criteria:

  • Active current disease or history of autoimmune disease
  • Active infection or history of severe infection within the previous 3 months (if at screening)
  • Known positive or chronically active or C
  • Administration of other medicinal product within 30 days of screening
  • Ongoing toxicity > grade 2 from previous standard or investigational therapies, according to US National Cancer Institute's
Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Diagnostic
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    Metastatic cancer patients

    Metastatic cancer patients before starting chemotherapy.

    Drug: [99mTc]Tc-HYNIC-FAPI

Interventions

  • Drug[99mTc]Tc-HYNIC-FAPI

    One single intravenous injection of \[99mTc\]Tc-HYNIC-FAPI, followed by gamma camera imaging after 2, 4, 6 and 24 hours.

    Also known as: Intravenous injection of [99mTc]Tc-HYNIC-FAPI

06

What researchers measure

Primary outcomes

  1. Gamma camera-based whole-body [99mTc]Tc-HYNIC-FAPI uptake value (%).

    Whole-body \[99mTc\]Tc-HYNIC-FAPI uptake coinciding with normal organs and tissues will be assessed using gamma camera and calculated as percentage (%) of the injected dose of the radiopharmaceutical.

    Time frame: 2, 4, 6 and 24 hours after injection.

  2. SPECT/CT-based [99mTc]Tc-HYNIC-FAPI value in tumor lesions (counts and SUV)

    99mTc\]Tc-HYNIC-FAPI uptake coinciding with tumor lesions will be assessed using single-photon emission computed tomography and measured in counts and SUV.

    Time frame: 2, 4 and 6 hours after injection.

  3. SPECT/CT -based [99mTc]Tc-HYNIC-FAPI background uptake value (counts and SUV).

    Focal uptake of \[99mTc\]Tc-HYNIC-FAPI in the regions without pathological findings will be assessed with SPECT/CT and measured in counts and SUV.

    Time frame: 2, 4 and 6 hours after injection.

  4. Tumor-to-background ratio (SPECT/CT).

    The SPECT/CT-based tumor-to-background ratio will be calculated as follows: the value of \[99mTc\]Tc-HYNIC-FAPI uptake coinciding with tumor lesions (counts) will be divided by the value of \[99mTc\]Tc-HYNIC-FAPI uptake coinciding with the regions without pathological findings (counts).

    Time frame: 2, 4 and 6 hours after injection.

Secondary outcomes

  1. Safety attributable to [99mTc]Tc-HYNIC-FAPI injections (Number of Participants with abnormal findings).

    The safety attributable to \[99mTc\]Tc-HYNIC-FAPI injections will be evaluated based on the assessments of physical examination, vital signs, and ECG (Number of Participants with abnormal findings relative to baseline).

    Time frame: 2, 4, 6 and 24 hours after injection.

  2. Safety attributable to [99mTc]Tc-HYNIC-FAPI injections (Number of Participants with abnormal laboratory findings).

    The safety attributable to \[99mTc\]Tc-HYNIC-FAPI injections will be evaluated based on the blood and urine laboratory tests (Number of Participants with abnormal laboratory findings relative to baseline).

    Time frame: 2, 4, 6 and 24 hours after injection.

  3. Safety attributable to [99mTc]Tc-HYNIC-FAPI injections (Number of Participants with incidence of adverse events).

    The safety attributable to \[99mTc\]Tc-HYNIC-FAPI injections will be evaluated based on the rate of adverse events (Number of Participants).

    Time frame: 2, 4, 6 and 24 hours after injection.

  4. Safety attributable to [99mTc]Tc-HYNIC-FAPI injections (Number of Participants with administration of concomitant medication).

    The safety attributable to \[99mTc\]Tc-HYNIC-FAPI injections will be evaluated based on the rate of administration of concomitant medication (Number of Participants).

    Time frame: 2, 4, 6 and 24 hours after injection.

07

Study locations

1 site
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Dec 2026, 10 months after the start.

Of 164 non-industry phase 1 interventional studies under Lung Neoplasms, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 35 and three quarters within 90. This study's planned 10 months is below that.

Counting every sponsor, half of 294 studies reached it within 52 months; a quarter within 28 and three quarters within 74.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 3, 2026
First posted
Mar 9, 2026
StartActual
Feb 26, 2026
Primary completionEst.
Dec 31, 2026
CompletionEst.
May 31, 2027
Last update
Jun 25, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 25, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07457541
Lead sponsor
Tomsk National Research Medical Center of the Russian Academy of Sciences
Responsible party
Sponsor
First posted
Mar 9, 2026
Start date
Feb 26, 2026
Primary completion
Dec 31, 2026 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Jun 25, 2026

Study contacts

Vladimir I Chernov, MD, Prof.
principal investigator · TomskNRMC Tomsk, Russia

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion